Cargando…

Validation of a Simple Quality‐of‐Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy

Minimal hepatic encephalopathy (MHE) is underdiagnosed because most clinics refrain from psychometric testing. Diagnostic activities need to go up so patients with MHE can get the treatment their condition requires. The sickness impact profile questionnaire for covert hepatic encephalopathy (SIPCHE)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauridsen, Mette Munk, Jepsen, Peter, Wernberg, Charlotte Wilhelmina, Schaffalitzky de Muckadell, Ove B., Bajaj, Jasmohan S., Vilstrup, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471424/ https://www.ncbi.nlm.nih.gov/pubmed/32923838 http://dx.doi.org/10.1002/hep4.1555

Ejemplares similares

Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis
por: Wernberg, Charlotte W., et al.
Publicado: (2019)

The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
por: Lauridsen, M. M., et al.
Publicado: (2017)

Reply to Letter to the Editor: Neurocognitive impairment in obesity and liver disease—An unsolved mystery
por: Wernberg, Charlotte Wilhelmina, et al.
Publicado: (2023)

Overt Hepatic Encephalopathy Experienced by Individuals With Cirrhosis: A Qualitative Interview Study
por: Ladegaard Grønkjær, Lea, et al.
Publicado: (2018)

Animal Naming Test – a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy
por: Agarwal, Ankit, et al.
Publicado: (2020)

Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests
por: Ehrenbauer, Alena F., et al.
Publicado: (2023)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Adventures in Developing an App for Covert Hepatic Encephalopathy
por: Bajaj, Jasmohan S
Publicado: (2017)

Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease—Current Knowledge, Mechanisms and Perspectives
por: Kjærgaard, Kristoffer, et al.
Publicado: (2021)

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
por: Safadi, Rifaat, et al.
Publicado: (2022)

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
por: Montagnese, Sara, et al.
Publicado: (2019)

Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2020)

Inadequate practices for hepatic encephalopathy management in the inpatient setting
por: Shaw, Jawaid, et al.
Publicado: (2022)

Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study
por: Jepsen, Peter, et al.
Publicado: (2016)

Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment
por: Hassouneh, Ramzi, et al.
Publicado: (2021)

IgG4-Related Sclerosing Cholangitis Involving the Intrahepatic Bile Ducts Diagnosed with Liver Biopsy
por: Thinesen, Malene Theilmann, et al.
Publicado: (2018)

Gene Expression Network Analysis of Precursor Lesions in Familial Pancreatic Cancer
por: Tan, Ming, et al.
Publicado: (2020)

Doppler-Guided Second-Look Endoscopy in Peptic Ulcer Bleeding: A Randomised Controlled Trial
por: Nielsen, Michael Milek, et al.
Publicado: (2023)

Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
por: Faccioli, Jessica, et al.
Publicado: (2023)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

The prevalence and risk factors for cognitive impairment in obesity and NAFLD
por: Wernberg, Charlotte W., et al.
Publicado: (2023)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri, Daniela Paola, et al.
Publicado: (2015)

Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated? — A Cross‐Sectional Study Using Liver Biopsy and Dual‐Energy X‐Ray Absorptiometry
por: Hansen, Stinus Gadegaard, et al.
Publicado: (2023)

Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup, Linda Skibsted, et al.
Publicado: (2019)

Update on the Therapeutic Management of Hepatic Encephalopathy
por: Kornerup, Linda Skibsted, et al.
Publicado: (2018)

Psychometric Hepatic Encephalopathy Score for the Diagnosis of Minimal Hepatic Encephalopathy in Thai Cirrhotic Patients
por: Thanapirom, Kessarin, et al.
Publicado: (2023)

Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2019)

Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis
por: Gairing, Simon J., et al.
Publicado: (2023)

Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors
por: Williams, Sydni, et al.
Publicado: (2021)

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients
por: Wernberg, Charlotte W., et al.
Publicado: (2021)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Neuroprotective Effect of Nortriptyline in Overt Hepatic Encephalopathy Through Attenuation of Mitochondrial Dysfunction
por: Jeong, Ji Heun, et al.
Publicado: (2018)

The Role of Presepsin in Diagnosing Infections in Patients with Liver Cirrhosis and Overt Hepatic Encephalopathy
por: Igna, Razvan, et al.
Publicado: (2022)

Splenomegaly – Diagnostic validity, work-up, and underlying causes
por: Curovic Rotbain, Emelie, et al.
Publicado: (2017)

Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice
por: Zwisler, Jon Eik, et al.
Publicado: (2015)

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2019)

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy
por: Abe, Kazumichi, et al.
Publicado: (2021)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer
por: Detlefsen, Sönke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_245nsa9c206g8fekpu3mqdrgn0